Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRGT-119 in Chronic Anal Fissure (Phase 2, randomized double-blind adaptive trial with open-label extension)
2019-000853-30Phase 2Terminated
- Sponsor
- DRGT
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAVT-119 in chronic anal fissure (CAF) (3 arms), sponsored by DRGT. Primary endpoint: Change from baseline in resting anal pressure at Day 42 (Part 1). Started Jun 2019; status: terminated.
02
Drugs
TAVT-119
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on 2019-000853-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000853-30.